Sign In
Buy LIFE
$16.89
-0.375 (-2.17%)
At Close: Jun 03, 2026
aTyr Pharma to Present at March Investor Conferences
01:00pm, Wednesday, 08'th Mar 2023 GlobeNewswire Inc.
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tR
aTyr Pharma to Present at March Investor Conferences
08:00am, Wednesday, 08'th Mar 2023
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
05:00pm, Friday, 17'th Feb 2023 Zacks Investment Research
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
01:33pm, Friday, 17'th Feb 2023
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
aTyr Pharma Announces Commencement of Public Offering of Common Stock
09:11pm, Wednesday, 08'th Feb 2023 GlobeNewswire Inc.
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRN
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:00pm, Friday, 18'th Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRN
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
10:15pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript
08:32pm, Thursday, 10'th Nov 2022
aTyr Pharma, Inc. (NASDAQ:LIFE ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Ashlee Dunston - Director, IR & Corporate Communications Sanjay Shukla - President &
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
06:48pm, Thursday, 10'th Nov 2022
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma to Present at Upcoming Investor Conferences
01:00pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRN
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
12:02pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
08:02am, Thursday, 03'rd Nov 2022
Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST
aTyr Pharma to Present at the Jefferies London Healthcare Conference
08:00am, Tuesday, 25'th Oct 2022
SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
11:49am, Tuesday, 16'th Aug 2022 Benzinga
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.
Wells Fargo lowered the price target on Charles River
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2022 Results - Earnings Call Transcript
11:13pm, Monday, 15'th Aug 2022
aTyr Pharma, Inc. (NASDAQ:LIFE ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Ashlee Dunston - Director, Investor Relations and Corporate Communications Sanjay Shuk
